Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,171 recruiting studies in this area right now.
By phase
- Not applicable9,517
- Phase 24,403
- Phase 12,662
- Phase 1/Phase 21,653
- Phase 31,392
- Phase 2/Phase 3284
- Phase 4260
Top conditions
- Breast Cancer1,197
- Prostate Cancer645
- Cancer634
- Colorectal Cancer481
- Lung Cancer417
- Ovarian Cancer337
- Multiple Myeloma329
- Pancreatic Cancer290
- Gastric Cancer283
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor234
- Head and Neck Cancer225
- Cervical Cancer224
- Endometrial Cancer209
- Advanced Solid Tumors202
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center142
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences141
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,410
- Texas635
- Arizona509
- Florida435
- Alabama427
- New York404
- Massachusetts340
- Maryland330
- New Jersey271
- Pennsylvania234
Recruiting studies20,171 total
- NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT05807789Recruiting
Genetic testing during CAR-T treatment for adults
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Bologna, ItalyAges 18–70 - NCT07542002RecruitingPhase 2
Chemotherapy and Radiation for Pancreatic Cancer Before Surgery
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
NingboAges 18–75 - NCT07540533RecruitingPhase 2
Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Zhengzhou, HenanAges 18 years+ - NCT07536087Recruiting
Heat treatment for pancreatic cysts and neuroendocrine tumors
This trial tests a minimally invasive endoscopic procedure that uses heat to treat certain pancreatic cysts (fluid-filled sacs) and small neuroendocrine tumors (hormone-producing growths). It may be an option if surgery isn't possible or if you prefer to avoid it.
PragueAges 18 years+ - NCT06750419RecruitingPhase 3
Imaging test for clear cell kidney cancer before surgery
This study tests a special imaging agent (89Zr-TLX250) to help doctors see clear cell kidney cancer during PET/CT scans. It is for people in China who have a single small kidney mass and are already scheduled for surgery to remove it.
BeijingAges 18 years+ - NCT06363994RecruitingPhase 3
Study of orelabrutinib plus BR for untreated mantle cell lymphoma
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
BeijingAges 60 years+ - NCT06430658RecruitingPhase 2
Combination treatment before surgery for unresectable esophageal cancer
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
BeijingAges 18–75 - NCT06554951Recruiting
Extracellular vesicles study in CAR-T cell therapy patients
This study looks at tiny particles called extracellular vesicles in the blood of people receiving CAR-T cell therapy for certain blood cancers. It may help researchers understand how these particles affect treatment outcomes.
Bologna, BolognaAges 18–90 - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT07539311RecruitingPhase 2
Testing Rina-S for Advanced Gastrointestinal Cancers
This study tests a new drug called Rina-S in people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have spread or cannot be surgically removed. The drug is designed to help slow or stop cancer growth in people whose cancer has gotten worse despite recent treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07541534RecruitingPhase 1
HLX316 immunotherapy for advanced solid tumors
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
ChongqingAges 18 years+ - NCT07537881RecruitingPhase 1/Phase 2
RC288 for solid tumors: a Phase 1/2 safety and effectiveness study
This study tests a new drug called RC288 to treat solid tumors (cancers that form lumps). Researchers want to see if it's safe and how well it works for people whose cancer hasn't responded to other treatments or has returned.
Hunan, ChangshaAges 18–75 - NCT07542210Recruiting
Understanding Why Patients Stop or Continue Lung Cancer Treatment
This research study asks lung cancer patients and their doctors about their experiences taking osimertinib (a targeted cancer medication) after surgery. Researchers want to understand what helps patients stay on this treatment and what makes it hard to continue, so they can better support patients in the future.
BeijingAges 18 years+ - NCT07538843Recruiting
Darolutamide Plus Hormone Therapy for Prostate Cancer in China
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Multiple LocationsAges 18 years+ - NCT07542041Recruiting
Pancreatic Cancer Detection Using Advanced Tissue Analysis
This study tests a new way to analyze tiny samples of pancreatic tissue taken during a biopsy to better detect cancer. The method uses special technology to examine the physical properties of cells, which may help doctors diagnose pancreatic cancer more accurately.
Tampa, FloridaAges 18 years+ - NCT07539844Recruiting
Study of Folate Receptor Alpha in High-Grade Serous Ovarian Cancer
This study examines tissue samples from women with a specific type of ovarian cancer (high-grade serous) to measure how much of a protein called folate receptor alpha is present. Understanding this protein level may help doctors identify which patients could benefit from targeted treatments in the future.
Buenos Aires, Buenos AiresAges 18 years+ - NCT07538804RecruitingPhase 1/Phase 2
Testing ANS02 for EGFR-Mutated Lung Cancer
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
Fairfax, VirginiaAges 18 years+ - NCT07542379RecruitingEarly Phase 1
A radioactive treatment for advanced prostate cancer
This early-stage trial tests a new radioactive drug (177Lu-FC516) designed to target and treat prostate cancer that has spread and is no longer responding to standard treatments. The goal is to evaluate whether it is safe and effective.
Wuxi, JiangsuAges 18 years+ - NCT07535112RecruitingPhase 1
Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT07539285RecruitingPhase 1
HDM2024 treatment for advanced solid tumors
This study tests a new cancer drug called HDM2024 in people with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have stopped responding to standard treatments. The drug is designed to target specific proteins called EGFR and HER3 on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07541170RecruitingPhase 3
Testing divarasib after lung cancer surgery and chemotherapy
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
Clovis, CaliforniaAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT06404905RecruitingPhase 1
Testing BT02 for advanced solid tumors
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
Beijing, BiejingAges 18–75
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,171 recruiting oncology studies from the U.S. registry right now, out of 30,126 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.